HomeMOLN • NASDAQ
add
Molecular Partners AG
Previous close
$4.28
Day range
$4.47 - $4.57
Year range
$3.36 - $5.91
Market cap
176.79M USD
Avg Volume
8.08K
P/E ratio
-
Dividend yield
-
Financials
Income Statement
Revenue
Net income
| (CHF) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.60M | -18.25% |
Net income | -11.84M | 27.85% |
Net profit margin | — | — |
Earnings per share | -0.33 | 32.65% |
EBITDA | -11.40M | 18.54% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 104.52M | -27.22% |
Total assets | 112.15M | -27.27% |
Total liabilities | 16.62M | 7.70% |
Total equity | 95.53M | — |
Shares outstanding | 37.40M | — |
Price to book | 1.68 | — |
Return on assets | -25.23% | — |
Return on capital | -29.02% | — |
Cash Flow
Net change in cash
| (CHF) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -11.84M | 27.85% |
Cash from operations | -9.93M | 25.27% |
Cash from investing | 10.66M | -25.01% |
Cash from financing | -304.00K | -1.00% |
Net change in cash | 384.00K | 481.82% |
Free cash flow | -5.40M | 33.24% |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
153
